Francesco Novelli, Ph.D.
Professor of Immunology & Director of Tumor Immunology Lab
Department of Molecular Biotechnology and Health Sciences
University of Turin & Center for Experimental Research and Medical Studies (CeRMS)
Turin University Hospital, Italy
Francesco Novelli, Ph.D. is a Professor of Immunology at the University of Turin and Director of Tumor Immunology Laboratory at the Center for Experimental and Medical Studies (CeRMS) of the Turin University Hospital. He received his B.S. degree in Biology from the University of Turin in 1984, and the Ph.D. in Physiopathology in 1993 from the University of L’Aquila in Italy. Between 1988 and 1996, he performed his graduate study and post-doctoral fellowship research in the Immunology Laboratory of Dr. Guido Forni at the University of Turin. During this period, he worked at Hoffmann-La Roche Molecular Biology Department in Basel, Switzerland with Prof. Gianni Garotta (1988~1989) and Wistar Institute of Anatomy and Biology, University of Pennsylvania with Prof. Giorgio Trinchieri (1993~1994). He has worked at Necker-Medical School Paris as Visiting Professor with Prof. Jean-Luis Casanova (2001-2002). Upon joining the faculty at the University of Turin, he was appointed as Assistant (1996), Associate (2006), and Full Professor (2016) in Immunology, and Director of Tumor Immunology Laboratory at CeRMS (2002).
In addition to his current roles as Professor of Immunology at the University of Turin and Director of Tumor Immunology Laboratory at the Turin University Hospital, he serves as Immunogenetist at the Transplantation Service of the Turin University Hospital and Chair of the Ph.D. Program of Molecular Medicine of University of Turin. He is Project Leader and shareholder of NatiMab Therapeutics (Turin).
His major scientific accomplishments include: 1) the definition of the role of IFN-g/IFN-gR interaction in the regulation of activation, differentiation, and death of normal and neoplastic T cells; 2) the demonstration that Th17 lymphocytes are expanded in relapsing/remitting multiple sclerosis patients and their insensitivity to type II IFN; 3) the identification of a number of pancreatic cancer associated antigens by a serological proteomics study; 4) the demonstration of the role played by alpha-enolase (ENO1) in the regulation of metabolism, adhesion, and migration of pancreatic cancer cells; and 5) the development of a ENO1-based DNA vaccination that results in robust immune responses, delays tumor progression, and significantly extends survival in genetically engineered mouse models of pancreatic cancer.
Shizuko Sei, M.D.
Chemopreventive Agent Development
Division of Cancer Prevention
National Cancer Institute
If you are interested in meeting with Dr. Novelli before or after the seminar, please contact Shizuko Sei, M.D., DCP, NCI at 240-276-5005 or email@example.com.